Beam prices $500M underwritten offering of common stock and pre-funded warrants

Beam Therapeutics Inc.

Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.
Gross proceeds ~$500.0M; net proceeds after discounts and expenses ~$469.7M.
Use of proceeds: platform technology, R&D for BEAM-101, BEAM-302 pivotal trial, ESCAPE conditioning trial, general corporate.
Closing expected March 11, 2025; J.P. Morgan, Jefferies, Cantor, Citigroup, Wells Fargo as joint bookrunners.
Pre-funded warrants exercisable immediately at $0.01 per share, with cashless exercise and beneficial ownership limitation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.